STOCK TITAN

Alpha Tau Medical Ltd Stock Price, News & Analysis

DRTS Nasdaq

Welcome to our dedicated page for Alpha Tau Medical news (Ticker: DRTS), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical stock.

Alpha Tau Medical Ltd (DRTS) is a clinical-stage oncology innovator advancing Alpha DaRT technology for targeted solid tumor treatment. This page consolidates all official corporate communications and verified news coverage related to clinical developments, regulatory progress, and strategic initiatives.

Investors and researchers will find timely updates on clinical trial outcomes, regulatory submissions, and technology partnerships critical for evaluating the company’s therapeutic pipeline. The curated news collection serves as a centralized resource for tracking milestones in alpha-radiation oncology solutions.

Content spans phase trial results, manufacturing expansions, and peer-reviewed study publications, providing comprehensive insight into the company’s progress. All materials are vetted for relevance to investment analysis and therapeutic development.

Bookmark this page for efficient monitoring of DRTS’ advancements in localized radiotherapy. Combine regular reviews with SEC filings and medical journals for complete due diligence.

Rhea-AI Summary

Alpha Tau Medical presented new preclinical data at the 2024 ESTRO Congress, showcasing the abscopal immune effect of Alpha DaRT in pancreatic murine tumor models. The data revealed a significant reduction in distant tumor growth rate, indicating potential benefits for future clinical trials and patient outcomes. CEO Uzi Sofer highlighted the promising results, emphasizing the therapy's potential in combination with immunotherapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
-
Rhea-AI Summary

Alpha Tau Medical announced that CFO Raphi Levy will present at investor conferences in May 2024. The company, known for its alpha-radiation cancer therapy Alpha DaRT™, will participate in events like Guggenheim Securities Radiopharmaceuticals Day and H.C. Wainwright BioConnect Investor Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.67%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.05%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.1%
Tags

FAQ

What is the current stock price of Alpha Tau Medical (DRTS)?

The current stock price of Alpha Tau Medical (DRTS) is $4.31 as of October 3, 2025.

What is the market cap of Alpha Tau Medical (DRTS)?

The market cap of Alpha Tau Medical (DRTS) is approximately 374.2M.
Alpha Tau Medical Ltd

Nasdaq:DRTS

DRTS Rankings

DRTS Stock Data

374.19M
57.16M
32.79%
2.28%
0.11%
Biotechnology
Healthcare
Link
Israel
Jerusalem